Krzysztof Dubiel

Celon Pharma (Poland) — Poland

Biochemistry, Genetics and Molecular Biology · Life Sciences

11h-index332citations36works1.72yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Receptor Mechanisms and Signaling(7), Computational Drug Discovery Methods(6), Diabetes Treatment and Management(4), Neuropeptides and Animal Physiology(4), Chemical Synthesis and Analysis(4)

Publications36 total

Identification of pyrrolo[2,3-d]pyrimidine-based dual MERTK and FLT3 inhibitor: Hit-to-lead, machine learning, modeling, synthesis, and biological evaluation
European Journal of Pharmaceutical Sciences·2026Open Access
Simultaneous 5-HT1BR agonist/5-HT6R antagonist action as a potential treatment of Parkinson’s disease and its comorbidities
Journal of Pharmacology and Experimental Therapeutics·2024· 5 citedOpen Access
Guanidine Derivative ADS1017, a Potent Histamine H<sub>3</sub> Receptor Antagonist with Promising Analgesic Activity and Satisfactory Safety Profile
ACS Chemical Neuroscience·2024· 2 citedOpen Access
Preclinical characterization of CPL304110 as a potent and selective inhibitor of fibroblast growth factor receptors 1, 2, and 3 for gastric, bladder, and squamous cell lung cancer
Frontiers in Oncology·2024· 3 citedOpen Access
Development of the telescoped flow Pd-catalyzed aerobic alcohol oxidation/reductive amination sequence in the synthesis of new phosphatidylinositide 3-kinase inhibitor (CPL302415)
RSC Advances·2024Open Access
A novel functional platform for the discovery of trace amine-associated receptor 1 agonists with dual gαs and gαq activity
Neuroscience Applied·2024Open Access
Quality by Design (QbD) and Design of Experiments (DOE) as a Strategy for Tuning Lipid Nanoparticle Formulations for RNA Delivery
Biomedicines·2023· 42 citedOpen Access
Fast Claisen condensation reaction optimization in a continuous flow reactor
Monatshefte für Chemie - Chemical Monthly·2023· 1 citedOpen Access
Tuning the Biological Activity of PI3Kδ Inhibitor by the Introduction of a Fluorine Atom Using the Computational Workflow
Molecules·2023· 2 citedOpen Access
Development and optimization of a continuous flow ester reduction with LiAlH<sub>4</sub> in the synthesis of a key intermediate for a PI3Kδ inhibitor (CPL302415)
Reaction Chemistry & Engineering·2023· 2 cited
Implementation of QbD Approach to the Development of Chromatographic Methods for the Determination of Complete Impurity Profile of Substance on the Preclinical and Clinical Step of Drug Discovery Studies
International Journal of Molecular Sciences·2022· 14 citedOpen Access
Design, Synthesis, and Development of pyrazolo[1,5-a]pyrimidine Derivatives as a Novel Series of Selective PI3Kδ Inhibitors: Part I—Indole Derivatives
Pharmaceuticals·2022· 4 citedOpen Access
Design, Synthesis, and Development of Pyrazolo[1,5-a]pyrimidine Derivatives as a Novel Series of Selective PI3Kδ Inhibitors: Part II—Benzimidazole Derivatives
Pharmaceuticals·2022· 9 citedOpen Access
The design of experiments (DoE) in optimization of an aerobic flow Pd-catalyzed oxidation of alcohol towards an important aldehyde precursor in the synthesis of phosphatidylinositide 3-kinase inhibitor (CPL302415)
RSC Advances·2022· 8 citedOpen Access
Discovery and development of CPL207280 as new GPR40/FFA1 agonist
European Journal of Medicinal Chemistry·2021· 14 cited
CPL207280, a Novel G Protein–Coupled Receptor 40/Free Fatty Acid Receptor 1–Specific Agonist, Shows a Favorable Safety Profile and Exerts Antidiabetic Effects in Type 2 Diabetic Animals
Molecular Pharmacology·2021· 12 citedOpen Access
Do Small Molecules Activate the TrkB Receptor in the Same Manner as BDNF? Limitations of Published TrkB Low Molecular Agonists and Screening for Novel TrkB Orthosteric Agonists
Pharmaceuticals·2021· 39 citedOpen Access
CCDC 2076005: Experimental Crystal Structure Determination
The Cambridge Structural Database·2021· 1 citedOpen Access
A novel JAK/ROCK inhibitor, CPL409116, demonstrates potent efficacy in the mouse model of systemic lupus erythematosus
Journal of Pharmacological Sciences·2021· 14 citedOpen Access
Discovery and optimization of novel pyrazole-benzimidazole CPL304110, as a potent and selective inhibitor of fibroblast growth factor receptors FGFR (1–3)
European Journal of Medicinal Chemistry·2020· 45 citedOpen Access
page 1 of 2Next →

Frequent Co-authors

Maciej Wieczorek(31), Jerzy Pieczykolan(19), Damian Smuga(13), Mikołaj Matłoka(13), Lidia Gurba-Bryśkiewicz(12), Joanna Hucz‐Kalitowska(10), Aleksandra Stańczak(9), Monika Lamparska‐Przybysz(9), Marcin Zagozda(9), Daria Zdżalik-Bielecka(8), Rafał Moszczyński-Pętkowski(8), Wioleta Maruszak(7), Mateusz Mach(7), Paweł Gunerka(7), Krzysztof Mulewski(6), Stanisław Michałek(6), Zbigniew Ochal(6), Abdellah Yamani(5), Paweł Zajdel(5), Andrzej J. Bojarski(5)